Endogenous Fungal Endophthalmitis in a Patient Admitted to Intensive Care and Treated with Systemic Steroid for COVID-19

Kaderli S. T., KARALEZLİ A., Citil B. E., SAATCİ A. O.

TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, vol.52, no.2, pp.139-141, 2022 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 2
  • Publication Date: 2022
  • Doi Number: 10.4274/tjo.galenos.2022.04324
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Directory of Open Access Journals
  • Page Numbers: pp.139-141
  • Keywords: Endogenous endophthalmitis, posterior uveitis, endogenous fungal endophthalmitis, coronavirus disease 2019
  • Dokuz Eylül University Affiliated: Yes


A 61-year-old woman presented to our clinic with complaints of decreased visual acuity, pain, and redness in her left eye. Best corrected visual acuity (BCVA) was 20/20 in the right eye and counting fingers at 3 meters in the left eye. On slit-lamp examination, 1+ cells were detected in the anterior chamber. Fundus examination revealed 1+ haze in the vitreous and multiple creamy-whitish lesions in the retina and vitreous. Her history included a diagnosis of coronavirus disease 2019 (COVID-19) one month earlier, for which she was hospitalized in the intensive care unit for 20 days and received systemic corticosteroid treatment. Vitreous culture yielded Candida athicans. The patient's nasopharyngeal swab sample was positive for COVID-19 by reverse transcription polymerase chain reaction test. BCVA was improved co 20/40 after amphotericin therapy (via incravicreal injection and intravenous routes), and the vitricis and choriorecinitis lesion regressed after 2 weeks of treatment. Two weeks later, intravenous amphotericin was discontinued and oral fluconazole treatment was started at a dose of 400 mg/day. At 3-month follow-up, her BCVA was 20/25 and no inflammatory reaction was observed in the anterior chamber and vitreous.